title: Menopause after breast cancer: a survey on breast cancer survivors.
abstract: Due to the younger age and the ever wider use of adjuvant chemotherapy and antiestrogens, menopausal symptoms are a frequent cause of concern for breast cancer patients.
  
  
  OBJECTIVE
  To determine the prevalence of menopausal symptoms, and to explore the attitudes toward Hormone Replacement Therapy (HRT) or other treatments and the willingness to take oestrogen in breast cancer patients.
  
  
  METHODS
  A questionnaire-based survey on 250 breast cancer patients treated and followed-up at our department. Of them 144 (Group A) were in postmenopause and 106 (Group B) were in premenopause at time of diagnosis.
  
  
  RESULTS
  Adjuvant therapy with tamoxifen or tamoxifen plus chemotherapy is associated with a significant worsening of menopause-related symptoms of women belonging to Group A. These women are more concerned about risk of breast cancer recurrence than about risk of osteoporosis (P=0.05) and heart disease (P=0.006). Seventy-eight percent are against the use of HRT; only 22% would consider taking HRT mainly for vasomotor symptoms relief and osteoporosis prevention. The incidence of vasomotor and dystrophic symptoms is significantly higher in women belonging to Group B treated with chemotherapy and/or hormonotherapy as compared with postmenopausal women (P<0.000 and P=0.02, respectively). Premenopausal women are more concerned about risk of breast cancer recurrence than older women (P=0.09) and at the same time are significantly more worried about the impairment of the quality of life due to adjuvant therapy (P=0.005). Younger women are more prone to consider HRT than postmenopausal women (P=0.05). Sixty-six percent are against HRT use, and 34% would consider taking HRT to alleviate vasomotor and dystrophic symptoms and to prevent osteoporosis.
  
  
  CONCLUSIONS
  Breast cancer survivors are interested to treatments that may improve their quality of life, but fear of HRT persists among these women and their doctors, despite new evidence suggesting the low probability of detrimental effects.
authors.affiliation: Academic Department of Gynecological Oncology, University of Turin, Mauriziano Umberto I degrees Hospital and Institute for Cancer Research and Treatment of Candiolo, Turin, Italy. nbiglia@mauriziano.it
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Biglia
authors.forename: Marilena
authors.initials: M
authors.lastname: Cozzarella
authors.forename: Franca
authors.initials: F
authors.lastname: Cacciari
authors.forename: Riccardo
authors.initials: R
authors.lastname: Ponzone
authors.forename: Riccardo
authors.initials: R
authors.lastname: Roagna
authors.forename: Furio
authors.initials: F
authors.lastname: Maggiorotto
authors.forename: Piero
authors.initials: P
authors.lastname: Sismondi
mesh_terms: D001294:Attitude to Health; D001943:Breast Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D015914:Estrogen Replacement Therapy / Q000523:psychology*; D005260:Female; D019584:Hot Flashes / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008593:Menopause; D008875:Middle Aged; D015995:Prevalence; D011788:Quality of Life; D011795:Surveys and Questionnaires; D017741:Survivors / Q000523:psychology*